Clinical Trials
79 trialsCabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors
University of California, San Diego
Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors
M.D. Anderson Cancer Center
CABOTHYROID
Grupo Espanol de Tumores Neuroendocrinos
Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy
University of California, Irvine
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
Novartis
CaboPoint
Ipsen
CheckMate040
Bristol-Myers Squibb
CONTACT-01
Hoffmann-La Roche
Cabozantinib and Pembrolizumab in Metastatic Pancreas
University of Kentucky
Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)
Washington University School of Medicine
Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer
National Cancer Institute (NCI)
UNICAB
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
CABRAMET
Centre Leon Berard
IRCI Gynae Sarcomas, High Grade Uterine Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
CABATEN
Grupo Espanol de Tumores Neuroendocrinos
Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer
Massachusetts General Hospital
ACTION
Fundacion Clinic per a la Recerca Biomédica
Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma
University of Colorado, Denver
Cabozantinib and Nivolumab for Carcinoid Tumors
Dana-Farber Cancer Institute
Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
CaPture
University of Leipzig
Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed
National Cancer Institute (NCI)
Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
National Taiwan University Hospital
NICARAGUA
Fundacion CRIS de Investigación para Vencer el Cáncer
Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma
M.D. Anderson Cancer Center
PemCab
University of Utah
Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
MERIDIAN
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer
Memorial Sloan Kettering Cancer Center
Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)
University of Utah
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
Exelixis
Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
Dana-Farber Cancer Institute
Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer
M.D. Anderson Cancer Center
PIVOT IO 011
Bristol-Myers Squibb
CABOMAYOR
Spanish Oncology Genito-Urinary Group
Cabozantinib for Adults With Advanced Soft Tissue Sarcoma
National Institutes of Health Clinical Center (CC)
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
National Cancer Institute (NCI)
Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
SCRI Development Innovations, LLC
Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer
National Cancer Institute (NCI)
NF105-CABO
University of Alabama at Birmingham
CANTATA
Calithera Biosciences, Inc
Cabozantinib With Topotecan-Cyclophosphamide
Dana-Farber Cancer Institute
CABOCOL-01
Centre Francois Baclesse
Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus
National Cancer Institute (NCI)
Cabozantinib for Advanced Urothelial Cancer
National Institutes of Health Clinical Center (CC)
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Calithera Biosciences, Inc
Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer
University of Colorado, Denver